Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Bioinformatics analysis revealed that BARD1 may be a predictive biomarker for prognosis of breast cancer.
|
31808361 |
2020 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
The BARD1 protein, which heterodimerizes with BRCA1, is encoded by a known breast cancer susceptibility gene.
|
30925164 |
2019 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
BARD1-mutated BC index patients showed a significantly younger mean age at first diagnosis (AAD; 42.3 years, range 24-60 years) compared with the overall study sample (48.6 years, range 17-92 years; P = 0.00347).
|
31036035 |
2019 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
BRCA1 or BRCA2 mutations were found in 7.3% of the subjects, 6.3% had a mutation in other breast cancer genes (PALB2, CHEK2, ATM, and BARD1), and 1.6% had mutations in genes not associated with breast cancer.
|
30933323 |
2019 |
Malignant neoplasm of breast
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
CircRNA_BARD1 (circ_0001098) was up-regulated in breast cancer with the treatment of TCDD and the up-regulation of circRNA_BARD1 could restrain cell proliferation, block cell cycle and promote cell apoptosis.
|
30521417 |
2018 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1.
|
29686231 |
2018 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Germline pathogenic variants in BARD1, BRCA1, BRCA2, PALB2, and RAD51D were associated with high risk (odds ratio > 5.0) of TNBC and greater than 20% lifetime risk for overall breast cancer among Caucasians.
|
30099541 |
2018 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Moreover, GUARDIN also sustains breast cancer 1 (BRCA1) stability by acting as an RNA scaffold to facilitate the heterodimerization of BRCA1 and BRCA1-associated RING domain protein 1 (BARD1).
|
29593331 |
2018 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Breast cancer susceptibility gene 1 (BRCA1) and binding partner BRCA1-associated RING domain protein 1 (BARD1) form an essential E3 ubiquitin ligase important for DNA damage repair and homologous recombination.
|
30383767 |
2018 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
For example, several sex-ratio genes were found to interact with brc-1 and brd-1, the orthologs of the human breast cancer genes BRCA1 and BARD1, respectively.
|
28506208 |
2017 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
However,other genes, such as ATM, PALB2, BRIP1, CHEK, BARD1, while lower in frequency, may also increase breast cancer risk.
|
29093764 |
2017 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Loss of heterozygosity studies suggest a causative role of the BARD1 mutation in the development of primary peritoneal cancer, but fail to confirm an association between germline ATM mutations and breast cancer development in this family.
|
28139868 |
2017 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
After exclusion of BRCA1, BRCA2, and syndromic breast cancer genes (CDH1, PTEN, and TP53), observed pathogenic variants in 5 of 16 genes were associated with high or moderately increased risks of breast cancer: ATM (OR, 2.78; 95% CI, 2.22-3.62), BARD1 (OR, 2.16; 95% CI, 1.31-3.63), CHEK2 (OR, 1.48; 95% CI, 1.31-1.67), PALB2 (OR, 7.46; 95% CI, 5.12-11.19), and RAD51D (OR, 3.07; 95% CI, 1.21-7.88).
|
28418444 |
2017 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Twenty patients (19%) were identified to carry deleterious mutations, of whom 13 (12%) were in the BRCA1 or BRCA2, 6 (6%) were in five other known breast cancer predisposition genes and 1 patient had a mutation in both BRCA2 and BARD1.
|
26757417 |
2016 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
CLINVAR |
Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.
|
26556299 |
2016 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
CLINVAR |
New concepts on BARD1: Regulator of BRCA pathways and beyond.
|
26738429 |
2016 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
CLINVAR |
Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing.
|
26681312 |
2016 |
Malignant neoplasm of breast
|
1.000 |
CausalMutation
|
disease |
CLINVAR |
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.
|
27433846 |
2016 |
Malignant neoplasm of breast
|
1.000 |
CausalMutation
|
disease |
CLINVAR |
Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care.
|
26786923 |
2016 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that TNBC patients are enriched for pathogenic BARD1 germline mutations as compared to control samples and high BC risk families.
|
26010302 |
2016 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
CLINVAR |
Candidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer.
|
26546047 |
2016 |
Malignant neoplasm of breast
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
BARD1 is expressed as splice variant isoforms in breast cancer.
|
27477900 |
2016 |
Malignant neoplasm of breast
|
1.000 |
CausalMutation
|
disease |
CLINVAR |
Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families.
|
26534844 |
2016 |
Malignant neoplasm of breast
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
BRCA1 and BARD1 expressions were performed by immunohistochemistry and immunofluorescence in 103 breast cancer tumors.
|
26395808 |
2015 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
A significant proportion of BRCA1 tumours were positive for PARP1 (non-cleaved), and negative for BARD1 and RAD51 compared with sporadic BC.
|
25690937 |
2015 |